Mutation-specific dual potentiators maximize rescue of CFTR gating mutants

BACKGROUND: The potentiator ivacaftor (VX-770) has been approved for therapy of 38 cystic fibrosis (CF) mutations (~10% of the patient population) associated with a gating defect of the CF transmembrane conductance regulator (CFTR). Despite the success of VX-770 treatment of patients carrying at lea...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Cyst Fibros
Asıl Yazarlar: Veit, Guido, Da Fonte, Dillon F., Avramescu, Radu G., Premchandar, Aiswarya, Bagdany, Miklos, Xu, Haijin, Bensinger, Dennis, Stubba, Daniel, Schmidt, Boris, Matouk, Elias, Lukacs, Gergely L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7190413/
https://ncbi.nlm.nih.gov/pubmed/31678009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2019.10.011
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller